TY - JOUR
T1 - Dosing of zoledronic acid throughout the treatment continuum in breast cancer
AU - Hadji, Peyman
AU - Gnant, Michael
AU - Aapro, Matti
AU - Lipton, Allan
AU - Coleman, Robert
N1 - Funding Information:
Dr. Lipton participated as a consultant for Amgen, Novartis, Merck, GlaxoSmithKline, and Monogram; received honoraria from Amgen, Pfizer, and Novartis; and received research funding from Amgen, Novartis, Monogram Biosciences, Oncogene Sciences, and Procter & Gamble.
Funding Information:
Dr. Hadji has received honoraria, unrestricted educational grants, and research funding from the following companies: Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Novartis, Novo Nordisk, Organon, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Solvay, and Wyeth.
PY - 2011/8
Y1 - 2011/8
N2 - Several bisphosphonates including zoledronic acid (ZOL) are approved for treating bone metastases from breast cancer (BC). Recent trials demonstrated that ZOL prevents bone loss and reduces disease recurrence in early BC. This review uses pharmacodynamic, efficacy, and safety data from phase III trials of ZOL in early through metastatic BC to evaluate the dosing regimens used in each setting. The dosing frequencies of ZOL in early stage versus metastatic BC (4. mg 2-4 times per year versus monthly) are based on the respective levels of bone resorption and tumor burden. Data from ongoing clinical trials suggest that monthly dosing facilitates potential synergy between ZOL and chemotherapy in intermediate-risk BC and during neoadjuvant therapy. Overall, available data indicate that treatment with ZOL at appropriate intervals determined by disease characteristics helps attain key therapeutic goals in BC-maintaining skeletal integrity, reducing disease recurrence, and improving clinical outcomes.
AB - Several bisphosphonates including zoledronic acid (ZOL) are approved for treating bone metastases from breast cancer (BC). Recent trials demonstrated that ZOL prevents bone loss and reduces disease recurrence in early BC. This review uses pharmacodynamic, efficacy, and safety data from phase III trials of ZOL in early through metastatic BC to evaluate the dosing regimens used in each setting. The dosing frequencies of ZOL in early stage versus metastatic BC (4. mg 2-4 times per year versus monthly) are based on the respective levels of bone resorption and tumor burden. Data from ongoing clinical trials suggest that monthly dosing facilitates potential synergy between ZOL and chemotherapy in intermediate-risk BC and during neoadjuvant therapy. Overall, available data indicate that treatment with ZOL at appropriate intervals determined by disease characteristics helps attain key therapeutic goals in BC-maintaining skeletal integrity, reducing disease recurrence, and improving clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=79960175587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960175587&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2010.07.017
DO - 10.1016/j.critrevonc.2010.07.017
M3 - Review article
C2 - 20846875
AN - SCOPUS:79960175587
SN - 1040-8428
VL - 79
SP - 175
EP - 188
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 2
ER -